Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Consulting agrmnt
Appointed director

CalEthos, Inc. (RSRT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/21/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs: "OID CONVERTIBLE PROMISSORY NOTE",
"SERIES A WARRANT THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED , OR ANY STATE SECURITIES LAWS IN RELIANCE ON EXEMPTIONS FROM REGISTRATION REQUIREMENTS UNDER SAID LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGIS...",
"RESTRICTED SHARE AWARD AGREEMENT CalEthos, Inc. * * * * * Participant: M1 Advisors LLC Grant Date: August 17, 2021 Number of Restricted Shares granted: 1,500,000 * * * * * THIS AWARD AGREEMENT , dated as of the Grant Date specified above, is entered into by and between CalEthos, Inc., a Nevada corporation , and the Participant specified above; and WHEREAS, it has been determined that it would be in the best interests of the Company to grant the Restricted Shares provided herein to the Participant. NOW, THEREFORE, in consideration of the mutual covenants and premises hereinafter set forth and for other good and valuable consideration, the parties hereto hereby mutually covenant and agree as follows: 1. Definitions . For purposes of this Agreement, the following terms shall have the meanings...",
"RESTRICTED SHARE AWARD AGREEMENT CalEthos, Inc. * * * * * Participant: Hyuncheol Kim Grant Date: August 17, 2021 Number of Restricted Shares granted: 10,000,000 * * * * * THIS AWARD AGREEMENT , dated as of the Grant Date specified above, is entered into by and between CalEthos, Inc., a Nevada corporation , and the Participant specified above; and WHEREAS, it has been determined that it would be in the best interests of the Company to grant the Restricted Shares provided herein to the Participant. NOW, THEREFORE, in consideration of the mutual covenants and premises hereinafter set forth and for other good and valuable consideration, the parties hereto hereby mutually covenant and agree as follows: 1. Definitions . For purposes of this Agreement, the following terms shall have the meanings ...",
"Warrant of CalEthos, Inc. to Mireya Lange",
"WHEREAS, the Company desires to retain the consulting services of the Consultant and to have the Consultant provide services as the Company’ s “Chief Executive Officer”, and the Company wishes to acquire and be assured of Consultant’ s consulting services on the terms and conditions hereinafter set forth; and WHEREAS, the Consultant desires to serve and consult with the Company on the terms and conditions hereinafter set forth.",
"WHEREAS, the Company desires to retain the consulting services of the Consultant and to have the Consultant serve as the Company’ s “Chief Technology Officer”, and the Company wishes to acquire and be assured of Consultant’ s consulting services on the terms and conditions hereinafter set forth; and WHEREAS, the Consultant desires to serve and consult with the Company on the terms and conditions hereinafter set forth.",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of September 15, 2021, by and among CalEthos Inc., a Nevada corporation , and the investor signatory hereto . This Agreement is made pursuant to the Subscription Agreement, dated on or about September 1, 2021 among the Company and the Investor covering $3,850,000 aggregate principal amount of a Company’ s OID Convertible Promissory Note and a stock purchase warrant to purchase up to 1,540,000 shares of common stock, par value $0.001 per share , of the Company, which warrant, if exercised in full for cash, will result in the issuance to the Investor of a stock purchase warrant to purchase up to 1,540,000 shares of Common Stock. The Company and the Investor hereby agree as follows: 1. Definitions . C..."
07/20/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "CalEthos Issues CEO Business Update"
04/15/2020 8-K Termination of a Material Definitive Agreement
01/17/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "RECITALS A. As of the date of this Agreement, Seller owns all of the issued and outstanding shares of common stock, no par value per share , of 1815 Carnegie Santa Ana Corp., a California general stock corporation . B. Seller desires to sell the Shares to Purchaser, and Purchaser desires to purchase the Shares from Seller, upon the terms and conditions set forth herein. C. Purchaser, or a wholly-owned subsidiary of Purchaser, and 1815 Carnegie LLC, a wholly-owned subsidiary of Seller, shall enter into that certain Lease Agreement on the Closing Date , substantially in the form attached hereto as Exhibit A , pursuant to which 1815 Carnegie LLC will agree to lease to Purchaser, and Purchaser will agree to lease from 1815 Carnegie LLC, that certain approximate 29,503-square-foot, free-standin...",
"Executive Summary Investor Presentation dated January 2020",
"Transcript of Virtual Tour video of Planned SHOWCASE Superstore and Event Center"
02/08/2019 8-K Quarterly results
10/29/2018 8-K Material Modifications to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Financial Statements and...
Docs: "Certificate of Amendment to Certificate of Designations",
"Letter from Novogradac & Company LLP"
09/14/2018 8-K Resignation/termination of a director
Docs: "Certificate of Designation of RealSource Residential, Inc",
"Series A Preferred Stock Purchase Agreement among RealSource Residential, Inc., and the purchasers of Series A Preferred Stock listed therein"
01/19/2016 8-K Quarterly results
10/02/2015 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from Li and Company, PC to the SEC"
12/13/2013 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of 12% Unsecured Convertible Promissory Note issued to Investors in the Offering",
"Form of Warrant issued to Investors in the Offering",
"Form of SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT , is dated as of _______________, 2013, by and between RealSource Residential, Inc., a Nevada corporation , and the subscriber signatory hereto . WHEREAS, the Company and Subscriber are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the provisions of Section 4 and/or Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission under the Securities Act of 1933, as amended ; and WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to Subscriber, and Subscriber shall purchase the Company, Units of the Company , with each Unit consisting of: a $10,000 face value ...",
"RIGHT OF FIRST REFUSAL OPTION"
07/19/2013 8-K Form 8-K - Current report
04/11/2013 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Shares for Debt Agreement"
10/01/2012 8-K Unregistered Sales of Equity Securities, Changes in Control of Registrant, Other Events
02/16/2012 8-K Form 8-K - Current report
11/15/2010 8-K Form 8-K - Current report
12/14/2009 8-K Form 8-K - Current report
08/31/2009 8-K Form 8-K - Current report
08/11/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Upstream Biosciences Seeks Licensors or Acquirers for Drug Discovery Portfolio and Cancer Diagnostic Platform Vancouver, British Columbia - August 10, 2009 - Upstream Biosciences Inc. today announced that the company is actively seeking licensors or acquirers for its novel anti-parasitic drug discovery portfolio and cancer diagnostic platform."
04/18/2008 8-K Form 8-K -- Current report
04/16/2008 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UPSTREAM BIOSCIENCES ANNOUNCES APPOINTMENT OF JEFFREY BACHA TO ITS BOARD OF DIRECTORS"
03/27/2008 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UPSTREAM BIOSCIENCES ANNOUNCES APPOINTMENT OF DR. GEERT CAUWENBERGH TO ITS BOARD OF DIRECTORS"
08/27/2007 8-K Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "UPSTREAM BIOSCIENCES ACQUIRES INNOVATIVE PLATFORM TECHNOLOGY AND DRUG CANDIDATES FOR TROPICAL PARASITIC DISEASES"
08/23/2007 8-K Entered into consulting agreement
Docs: "Share Exchange Agreement dated August 17, 2007, among our company, Pacific Pharma Technologies, and the shareholders of Pacific Pharma Technologies"
07/10/2007 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UPSTREAM BIOSCIENCES INC. ANNOUNCES AGREEMENT WITH GENPATHWAY, INC. TO ADVANCE BIOMARKER VALIDATION STUDIES"
05/07/2007 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Upstream Biosciences Inc. Announces the Successful Closing of its $1.50 Unit Financing May 7, 2007 - Upstream Biosciences Inc. , is pleased to announce that the Company has successfully closed the second and final tranche of its unit financing announced on February 26, 2007. As per the terms of the deal, Upstream successfully completed all the required corporate milestones and has now received the remaining $1,000,000 for total proceeds of $2,000,000. On the closing date of the second tranche financing, the Company issued an additional 666,667 shares and 1,333,334 Series A and Series B warrants. The units were issued at $1.50 per unit, with each unit consisting of one common share, 1 Series A share purchase warrant and 1 Series B share purchase warrant. Each Series A share purchase warrant..."
04/30/2007 8-K Appointed a new director
Docs: "Upstream Biosciences Inc. Appoints Dr. Dale Pfost to Board of Directors April 30th, 2007 - Upstream Biosciences Inc. , an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has appointed Dr. Dale Pfost to the Company's board of directors. Dr. Pfost is currently President of Opko Health and former CEO of Acuity Pharmaceuticals, Orchid BioSciences, and Oxford GlycoSciences. "Dale has a proven track record of building successful Life Science companies," says Upstream CEO, Joel Bellenson. “His experience ranges from innovative research tools to revolutionary new drugs, and he has been a visionary in the world of molecular profiling.” Dr. Pfost has been a biotechnology entrepreneur and leader in the commercialization of new diagnostic/analytical ..."
03/29/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/19/2007 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
11/30/2006 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
10/06/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: the Company intends to use samples acquired from JTAT for validation of its biomarkers; the Company is able to secure well characterized samples; the Company is able to develop diagnostic tests that may aid in the earl..."
09/27/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Upstream Biosciences Inc. Announces Provisional Patent Filing of Thyroid Cancer Biomarkers September 26, 2006 - Upstream Biosciences Inc. , an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that, on September 25, 2006 it filed a provisional patent application with the U.S. Patent and Trademark Office for certain thyroid cancer biomarkers that could be useful for determining whether patients have a genetic risk of developing thyroid cancer. The American Cancer Society estimates that in the year 2006 about 30,180 new cases of thyroid cancer will be diagnosed in the United States. The disease is much more common in women than men, and of the new cases diagnosed, about 22,590 will occur in women, and 7,590 in men. Near..."
09/14/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Upstream Biosciences Inc. Announces Provisional Patent Filing of Ovarian Cancer Biomarkers - Upstream Biosciences Inc. , an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that, on September 12, 2006, it filed a provisional patent application with the U.S. Patent and Trademark Office for certain ovarian cancer biomarkers that could be useful for determining whether patients have a genetic risk of developing ovarian cancer. According to the American Cancer Society , Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. It is estimated that there will be about 15,310 deaths from ovarian cancer in the United States during 2006. Furth..."
09/13/2006 8-K Other Events
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy